This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across biosimilars, gene therapy, microbiome, robotics, ribozyme, and protein therapy. The TOE also provides technological analysis for recent developments in animal protein applications, microbiome, and cell cultures.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Recent Advancements in the Biotech Industry
- Alytix
- Amega Biotech
- AskBio
- Konica Minolta
- SoftBank
- Ranomics Inc.,
- aBioBot Inc.
- DoseBiome
- Clara Foods
- Circularis Biotechnologies Inc.
- SyntheX Labs
- MycoWorks
- mFluiDx Inc.
- ARDA
- Aurinia Pharmaceuticals
- Omeros
- Johnson & Johnson’s Ethicon
- Ardelyx
- Brigham and Women’s Hospital
- University of Utah
Key Industry Contacts
- Key Contacts
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- aBioBot Inc.
- ARDA
- Alytix
- Amega Biotech
- Ardelyx
- AskBio
- Aurinia Pharmaceuticals
- Brigham and Women’s Hospital
- Circularis Biotechnologies Inc.
- Clara Foods
- DoseBiome
- Johnson & Johnson’s Ethicon
- Konica Minolta
- mFluiDx Inc.
- MycoWorks
- Omeros
- Ranomics Inc.,
- SoftBank
- SyntheX Labs
- University of Utah
